Using highly focused revolving radiation beams, stereotactic body radiation therapy (SBRT) can focus on tumor sites while minimizing the irradiation to the surrounding normal tissues, which is different from traditional radiotherapy.\(^1\) Although it may cause difficult to manage toxicity, such as stenosis, ulceration, fibrosis, and even necrosis sometimes, it holds advantages such as high accuracy, noninvasiveness, and convenient outpatient treatment.\(^2\) Similarly, Tumor ablation has been widely used in the clinical treatment of cancer because of its advantages of minimal invasiveness, high operability, and good repeatability. The most commonly used ablation methods are microwave ablation (MWA), radiofrequency ablation (RFA) and cry ablation, among which MWA and RFA belong to thermal ablation. In addition, irreversible electroporation may play an increasing role in the treatments of solid tumors.\(^3\)

Stereotactic body radiation therapy, developed from stereotactic radiosurgery in the treatment of brain and spinal lesion, is commonly used in the treatment of early peripheral lung cancer and is increasingly used in the treatment of other primary or metastatic tumors.\(^4,5\) Many studies were done to explore its application in early nonsmall-cell lung cancer.\(^6\)\(^-\)\(^10\) Halperm et al\(^11\) compared the toxicities and cost of proton radiation, intensity-modulated radiotherapy (IMRT), and SBRT among younger men with prostate cancer. They showed that SBRT and IMRT had similar toxicity, but SBRT was cheaper than IMRT. de Geus et al\(^12\) evaluated the impact of SBRT on survival of patients with unresectable pancreatic cancer. Compared to chemotherapy alone or chemotherapy in combination with traditional fractionated external-beam radiotherapy, SBRT had a survival advantage. These results support SBRT as a promising treatment for patients with unresectable pancreatic cancer. Lazzari et al\(^13\) evaluated SBRT for patients with metachronous oligometastatic ovarian cancer in reference to local control, toxicity, delay of systemic treatment, and survival outcomes. Results showed good local control with a favorable toxicity profile. Altogether, SBRT may be an attractive option for some cancers in specific clinical scenarios.

Ablation techniques have also made great progress in the treatment of solid tumors in recent years. For very early and early stage hepatocellular carcinoma (HCC), RFA has been recommended as a feasible alternative to surgical resection and liver transplantation. For HCC \(>2\) cm, RFA combined with chemoembolization can contribute to near-curative therapy.\(^14,15\) A Markov modeling study conducted by Pollom et al\(^16\) showed that SBRT for initial treatment of localized, inoperable HCC was not cost-effective compared to RFA. However, SBRT is the preferred salvage therapy for local progression after RFA. Rajyaguru et al\(^17\) analyzed the National Cancer Database and drew similar conclusions. In a study by Zhuo et al,\(^18\) ultrasonographically-guided MWA was effective and safe for managing secondary hyperparathyroidism (SHPT) glands, providing rationale to use MWA for an alternative therapy for patients who are unable or refuse to undergo parathyroidectomy refractory or for patients having drug-resistant SHPT. Irreversible electroporation is a new tumor ablation technique that uses a pulsed electric field to create irreversible nanoscale pores on the cell membrane, thereby killing tumor cells. It has been attempted in liver tumor,\(^19\)\(^-\)\(^21\) pancreatic tumor,\(^22\)\(^-\)\(^24\) renal tumor,\(^25\) among others. Furthermore, immunomodulatory drugs have the potential to enhance systemic anticancer immune effects induced by local thermal ablation, and several studies have investigated strategies for combining immunoadjuvants with thermal ablation to stimulate stronger
antitumor responses with a hope for a systemic immune response.\textsuperscript{3,26}

This Special Collection comprises 9 articles about the SBRT or ablative therapies for solid tumors, such as breast cancer, colorectal cancer, oral cancer, intracranial tumors, lung cancer, and liver cancer. Sutter et al\textsuperscript{27} evaluated the feasibility, safety, and local efficacy of liver ablations assisted by a novel guiding tool—three dimensional (3D)-virtual target fluoroscopic display, which showed that 3D-virtual target fluoroscopic display improved visibility of tumors in recessed areas. Yuan et al\textsuperscript{28} evaluated the efficacy and safety of transarterial chemoembolization (TACE) combined with RFA in the treatment of small HCC in special areas. They found that the combination of RFA and TACE appears to be effective and safe. Wang et al\textsuperscript{29} assessed the overall survival (OS) and prognostic factors of laparoscopic MWA as a first-line treatment for HCC located at the liver surface infeasible for percutaneous ablation. They found laparoscopic MWA effective and well tolerated, and tumor number and ALT could be identified as independent predictors of reference-free survival while alpha fetoprotein (AFP) could be identified as independent predictor of OS. These results suggested that laparoscopic MWA could act as a treatment choice for patients with HCC with tumors at the liver surface improper for percutaneous approach. Studies conducted by Shen et al\textsuperscript{30} investigated the effect of microwave-assisted liver resection for HCC, showing that MWA-assisted liver resection enabled liver resection with lower recurrence rate.

In regard to SBRT, Reynaud et al\textsuperscript{31} investigated the safety and survival outcomes of hypofractionated stereotactic radiation therapy in the treatment for recurrent high-grade glioma. Hypofractionated stereotactic radiation therapy was well tolerated and provides an effective salvage option for recurrent high-grade gliomas with encouraging OS (15.6 months). Wee et al\textsuperscript{32} compared the intra/interobserver variabilities of gross target volumes between computed tomography and magnetic resonance imaging in patients with lung cancer receiving SBRT.

Additionally, Li et al\textsuperscript{33} investigated the prognostic value of pathologic features of oral squamous cell carcinoma in patients underwent seed implantation after radical surgery. They found that detailed microscopic description, particularly vascular infiltration, may help to identify patients who were more apt to tumor recurrence after treatment. Huang et al\textsuperscript{34} explored the role of programmed death-1 (PD-1) in the recurrence of breast cancer after radiotherapy, showing that the recurrence-free mean survival of PD-1 low expression group was significantly longer than that in PD-1 high expression group (68 vs 56 months). These results suggested that the expression level of PD-1 could be a potential prognostic biomarker for patients with breast cancer after surgery and radiotherapy.

Although some studies in this Special Collection may have some shortcomings, such as retrospective nature, single-center observation, and selection bias, we can still get some clinical advice from these studies. Nonetheless, we are yet on the way to get better evidence on the safety, efficacy, and indications of SBRT and ablative therapies for patient with solid tumors.

**Authors’ Note**
Jing Zhu and Yong Xu are co-first authors.

**ORCID iD**
Xiao-Jie Lu @ https://orcid.org/0000-0002-1595-6414

**References**

1. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44-54.

2. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847-2854.

3. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199-208.

4. Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K. Stereotactic body radiation therapy: scope of the literature. Annals of internal medicine. 2011;154(11):737-745.

5. Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol). 2018;30(1):5-14.

6. Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Ther Adv Med Oncol. 2018;10:175883591878989.

7. Przybysz D, Bradley JD. Challenging situations for lung SBRT. J Thorac Oncol. 2017;12(6):916-918.

8. Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer. 2018;124(4):667-678.

9. Verma V, Shostrom VK, Kumar SS, et al. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. Cancer. 2017;123(4):688-696.

10. Yau V, Lindsay P, Le L, et al. Low incidence of esophageal toxicity after lung stereotactic body radiation therapy: are current esophageal dose constraints too conservative? Int J Radiat Oncol Biol Phys. 2018;101(3):574-580.

11. Halpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016;122(16):2496-2504.

12. de Geus SWL, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123(21):4158-4167.

13. Lazzari R, Ronchi S, Gandini S, et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: A step toward a drug holiday. Int J Radiat Oncol Biol Phys. 2018;101(3):650-660.

14. European Association for the Study of the Liver. Electronic address cee, European Association for the Study of the L. EASL
Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2018;69(1):89-908.

15. Kim YS, Lim HK, Rhim H, Lee MW. Ablation of hepatocellular carcinoma. *Best Pract Res Clin Gastroenterol*. 2014;28(5):897-908.

16. Pollock EL, Lee K, Durkee BY, et al. Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a markov modeling study. *Radiology*. 2017;283(2):460-468.

17. Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. *J Clin Oncol*. 2018;36(6):600-608.

18. Zhuo L, Peng LL, Zhang YM, et al. US-guided microwave ablation of hyperplastic parathyroid glands: safety and efficacy in patients with end-stage renal disease: a pilot study. *Radiology*. 2017;282(2):576-584.

19. Barabasch A, Distelmaier M, Heil P, Krammer NA, Kuhl CK, Brunner P. Magnetic resonance imaging findings after percutaneous irreversible electroporation of liver metastases: a systematic longitudinal study. *Invest Radiol*. 2017;52(1):23-29.

20. Figini M, Wang X, Lyu T, et al. Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging. *Am J Transl Res*. 2017;9(2):580-590.

21. Langan RC, Goldman DA, D’Angelica MI, et al. Recurrence patterns following irreversible electroporation for hepatic malignancies. *J Surg Oncol*. 2017;115(6):704-710.

22. Latouche EL, Sano MB, Lorenzo MF, Davalos RV, Martin RCG. Irreversible electroporation for the ablation of pancreatic malignancies: a patient-specific methodology. *J Surg Oncol*. 2017;115(6):711-717.

23. Lin M, Alnaggar M, Liang S, et al. Circulating tumor DNA as a sensitive marker in patients undergoing irreversible electroporation for pancreatic cancer. *Cell Physiol Biochem*. 2018;47(4):1556-1564.

24. Vogel JA, Rombouts SJ, de Rooij T, et al. Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA): a prospective cohort study. *Ann Surg Oncol*. 2017;24(9):2734-2743.

25. Sorokin I, Lay AH, Reddy NK, Canvasser NE, Chamarty M, Cadeddu JA. Pain after percutaneous irreversible electroporation of renal tumors is not dependent on tumor location. *J Endourol*. 2017;31(8):751-755.

26. Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations—boosting the anticancer immune response. *J Immunother Cancer*. 2017;5(1):78.

27. Sutter O, Fihri A, Ourabia-Belkacem R, Sellier N, Ditallo A, Seror O. Real-time 3D virtual target fluoroscopic display for challenging hepatocellular carcinoma ablations using cone beam CT. *Technology in cancer research & treatment*. 2018;17:153303381878963.

28. Yuan W, Yang MJ, Xu J, et al. Radiofrequency ablation combined with transarterial chemoembolization for specially located small hepatocellular carcinoma. *Technol Cancer Res Treat*. 2018;17:1533033818788529.

29. Wang T, Zhang XY, Lu X, et al. Laparoscopic microwave ablation of hepatocellular carcinoma at liver surface: technique effectiveness and long-term outcomes. *Technol Cancer Res Treat*. 2019. doi:10.1177/1533033818824338.

30. Shen H, Zhou S, Lou Y, et al. Microwave-assisted ablation improves the prognosis of patients with hepatocellular carcinoma undergoing liver resection. *Technol Cancer Res Treat*. 2018. doi:10.1177/1533033818785980.

31. Reynaud T, Berta T, Farah W, et al. Hypofractionated stereotactic radiotherapy as a salvage therapy for recurrent high-grade gliomas: Single-center experience. *Technol Cancer Res Treat*. 2018. doi:10.1177/1533033818806498.

32. See CW, An HJ, Kang HC, Kim HJ, Wu HG. Variability of gross tumor volume delineation for stereotactic body radiotherapy of the lung with Tri-60Co magnetic resonance image-guided radiotherapy system (ViewRay): a comparative study with magnetic resonance- and computed tomography-based target delineation. *Technol Cancer Res Treat*. 2018;17:1533033818787383.

33. Jie WP, Bai JY, Li BB. Clinicopathologic analysis of oral squamous cell carcinoma after 125I interstitial brachytherapy. *Technol Cancer Res Treat*. 2018. doi:10.1177/1533033818806906.

34. Huang R, Cui Y, Guo Y. Programmed cell death protein-1 predicts the recurrence of breast cancer in patients subjected to radiotherapy after breast-preserving surgery. *Technol Cancer Res Treat*. 2018;17:1533033818793425.